Phase 2 Study Of Axitinib In Patients With Neurofibromatosis Type 2 (NF2) And Progressive Vestibular Schwannomas
Brief description of study
If you have been diagnosed with Neurofibromatosis Type 2 (NF2), a condition that mainly affects the skin and nervous system causing non-cancerous tumors to grow on the nerves around a person’s body, and have growing NF2-related tumors (abnormal growths of body tissue) called vestibular schwannomas (VS), you may qualify to participate in a clinical trial evaluating the effect of the drug AXITINIB. The main goal of this phase II trial is to determine if the study drug, AXITINIB may shrink tumors commonly found in patients with NF2 or stop them from growing.
Clinical Study Identifier: S14-00004
ClinicalTrials.gov Identifier: NCTS14-00004
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
